Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.52 |
| ▸ | NCS1 | P62166 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1084583 | 0.88 | RXFP1 (0.65) | RXFP1NCS1KDM4EHPGDKMT2A | |
| SCHEMBL939648 | 0.85 | RXFP1 (0.59) | RXFP1NCS1KDM4EHPGDKMT2A | |
| SCHEMBL1084999 | 0.81 | RXFP1 (0.64) | RXFP1NCS1KDM4EHPGDGAA | |
| SCHEMBL939649 | 0.79 | RXFP1 (0.68) | RXFP1NCS1KDM4EHPGDGAA | |
| SCHEMBL11798005 | 0.76 | KMT2A (0.60) | KDM4EKMT2AGAAMAPTTSHR | |
| SCHEMBL12912325 | 0.73 | KCNMA1 (0.73) | KDM4EKMT2AGAAMAPTTSHR | |
| SCHEMBL11789635 | 0.72 | KCNK3 (0.68) | RXFP1KDM4EKMT2AGAAMAPT | |
| SCHEMBL27848838 | 0.71 | KMT2A (0.77) | RXFP1KMT2AGAAMAPTTSHR | |
| SCHEMBL1308706 | 0.71 | KCNMA1 (0.74) | KDM4EHPGDKMT2AGAAMAPT | |
| SCHEMBL2271934 | 0.71 | ACLY (0.64) | KDM4EKMT2AGAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110021495-A1 | QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1608632-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-09-28 | — | — | US | disclosed |
| EP-1608632-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-09 | — | — | US | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | KCNN3, KCNN2, CACNA1I | RXFP1 3120/4885NCS1 121/4885KDM4E 2502/4885 |
| US-20110021495-A1 | QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNN3, CACNA1I, CACNA1B | RXFP1 3493/4885NCS1 114/4885KDM4E 2359/4885 |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | RXFP1 3120/4885NCS1 121/4885KDM4E 2502/4885 |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | RXFP1 3120/4885NCS1 121/4885KDM4E 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.